Centerbridge Partners - Q1 2020 holdings

$412 Million is the total value of Centerbridge Partners's 40 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 133.3% .

 Value Shares↓ Weighting
ARA  AMERICAN RENAL ASSOCS HLDGS$116,441,000
-36.3%
17,615,8360.0%28.25%
-4.5%
GNK  GENCO SHIPPING & TRADING LTD$67,324,000
-39.5%
10,486,6220.0%16.33%
-9.4%
HGV  HILTON GRAND VACATIONS INC$64,658,000
-54.1%
4,100,0000.0%15.68%
-31.3%
PCG SellPG&E CORP$43,208,000
-48.6%
4,806,259
-37.9%
10.48%
-23.0%
LQD NewISHARES TRiboxx inv cp etf$24,702,000200,000
+100.0%
5.99%
FOCS  FOCUS FINL PARTNERS INC$20,751,000
-21.9%
901,8350.0%5.03%
+17.0%
PCG NewPG&E CORPcall$17,980,0002,000,000
+100.0%
4.36%
SellENSCO JERSEY FIN LTDnote 3.000% 1/3$13,345,000
-73.3%
51,329,000
-27.3%
3.24%
-60.1%
SGRY NewSURGERY PARTNERS INC$6,772,0001,037,000
+100.0%
1.64%
STAY NewEXTENDED STAY AMER INCunit 99/99/9999b$5,927,000810,791
+100.0%
1.44%
CYH NewCOMMUNITY HEALTH SYS INC NEW$5,671,0001,697,800
+100.0%
1.38%
TEVA SellTEVA PHARMACEUTICAL INDS LTDput$5,209,000
-37.6%
580,000
-32.0%
1.26%
-6.5%
NewBLACKSTONE MTG TR INCnote 4.375% 5/0$5,137,0006,503,000
+100.0%
1.25%
GNW SellGENWORTH FINL INCput$5,098,000
-54.8%
1,535,500
-40.1%
1.24%
-32.3%
UNIT NewUNITI GROUP INCput$3,015,000500,000
+100.0%
0.73%
MNKKQ NewMALLINCKRODT PUB LTD CO$2,307,0001,165,000
+100.0%
0.56%
ENDP NewENDO INTL PLC$2,220,000600,000
+100.0%
0.54%
NewBLACKSTONE MTG TR INCnote 4.750% 3/1$1,570,0002,000,000
+100.0%
0.38%
TEVA NewTEVA PHARMACEUTICAL INDS LTDsponsored ads$898,000100,000
+100.0%
0.22%
RLGY ExitREALOGY HLDGS CORP$0-235,000
-100.0%
-0.37%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-05-15
Signatures

The EDGAR filing(s) were signed by:

About Centerbridge Partners

Centerbridge Partners is a private investment management firm that was founded in 2005 by Mark Gallogly and Jeffrey Aronson. The firm is headquartered in New York City and has additional offices in London and Hong Kong. Centerbridge Partners manages over $25 billion in assets across a range of investment strategies, including private equity, distressed debt, and real estate.

The firm has a strong leadership team, with Mark Gallogly serving as the CEO and Jeffrey Aronson as the Chairman and Chief Investment Officer. The COO is William Rahm, who oversees the firm's operations and infrastructure.

Centerbridge Partners has a reputation for being a highly disciplined and opportunistic investor, with a focus on identifying undervalued assets and unlocking value through operational improvements. The firm has a track record of successfully investing in a range of industries, including healthcare, energy, and financial services.

One notable investment made by Centerbridge Partners was its acquisition of Syncora Holdings, a financial guarantee insurance company, in 2013. The firm was able to turn around the struggling company by implementing operational improvements and strategic initiatives, ultimately leading to a successful exit.

Overall, Centerbridge Partners is a well-respected investment management firm with a strong leadership team and a proven track record of success.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GENCO SHIPPING & TRADING LTD26Q4 202218.0%
AMERICAN RENAL ASSOCS HLDGS19Q4 202034.8%
EXTENDED STAY AMER INC18Q4 202064.1%
AMBAC FINL GROUP INC17Q1 20184.8%
QUAD / GRAPHICS INC16Q4 20176.1%
IRSA INVERSIONES Y REP S A16Q3 20191.4%
ALLY FINL INC15Q4 201712.4%
WMIH CORP13Q3 20182.5%
CRESUD S A C I F Y A13Q4 20160.8%
ATLANTICA YIELD PLC12Q1 20199.0%

View Centerbridge Partners's complete holdings history.

Latest significant ownerships (13-D/G)
Centerbridge Partners Q1 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
KV PHARMACEUTICAL CO /DE/March 03, 2011? ?

View Centerbridge Partners's complete significant-ownership history.

Latest filings
TypeFiled
40-APP/A2024-03-04
13F-HR2024-02-14
13F-HR2023-11-14
40-APP2023-10-16
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16

View Centerbridge Partners's complete filings history.

Compare quarters

Export Centerbridge Partners's holdings